Table 4.
Top 10 medications concurrently used by cSLE LN patients with and without rituximab treatment
Medication | No Rituximab (N=161) | Treatment with Rituximab (N=55) |
---|---|---|
Hydroxychloroquine | 155 (96.3%) | 53 (96.4%) |
Mycophenolate Mofetil | 127 (78.9%) | 48 (87.3%) |
Cyclophosphamide | 26 (16.2%) | 37 (67.3%) |
Aspirin | 13 (8.1%) | 9 (16.4%) |
Mycophenolic Acid | 18 (11.8%) | 7 (12.7%) |
Angiotensin Converting Enzyme Inhibitor |
20 (12.4%) | 7 (12.7%) |
Azathioprine | 18 (11.2%) | 7 (12.7%) |
Lisinopril | 14 (8.7%) | 7 (12.7%) |
Vitamin D | 47 (29.2%) | 7 (12.7%) |
Immunoglobulin | 1 (0.6%) | 6 (10.9%) |
Tacrolimus | 7 (4.4%) | 6 (10.9%) |